SCHEMBL5636700

SCHEMBL5636700

COc1ccc(-c2cc3c4c(c2)[C@@H]2CNCC[C@@H]2N4CCCS3)c(F)c1

nearest known ligand 0.68

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 12/20 0.68
HTR2B P41595 6/20 0.58
HTR2A P28223 6/20 0.58
FPR1 P21462 2/20 0.33
ALDH1A1 P00352 2/20 0.33
FPR2 P25090 1/20 0.33
USP2 O75604 1/20 0.33
MAPT P10636 1/20 0.33
DRD2 P14416 3/20 0.32
JAK2 O60674 1/20 0.32
JAK3 P52333 1/20 0.32
PTK2 Q05397 1/20 0.32
KDM1A O60341 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5636958 0.91 HTR2C (0.62) HTR2CHTR2BHTR2A
SCHEMBL5638466 0.90 HTR2C (0.61) HTR2CHTR2BHTR2AALDH1A1
SCHEMBL5636633 0.90 HTR2C (0.61) HTR2CHTR2BHTR2ADRD2
SCHEMBL5638690 0.89 HTR2C (0.75) HTR2CHTR2BHTR2A
SCHEMBL5637149 0.88 HTR2C (0.59) HTR2CHTR2BHTR2ADRD2
SCHEMBL5636494 0.87 HTR2C (0.58) HTR2CHTR2BHTR2ADRD2
SCHEMBL6752987 0.87 HTR2C (0.58) HTR2CHTR2BHTR2ADRD2
SCHEMBL5636095 0.87 HTR2C (0.58) HTR2CHTR2BHTR2ADRD2
SCHEMBL5636294 0.87 HTR2C (0.58) HTR2CHTR2BHTR2ADRD2
SCHEMBL5636580 0.87 HTR2C (0.58) HTR2CHTR2BHTR2ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE39679-E1 Substituted heterocycle fused gamma-carbolines BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2007-06-05 US disclosed
US-6713471-B1 SUCH AS TERT-BUTYL-1-METHYL-6,7,9,12-TETRAHYDRO-5H-PYRIDO-(4,3-B)(1,4) THIAZEPINO(2,3,4-HI)INDOLE-11(10H)-CARBOXYLATE; SEROTONIN AGONISTS AND ANTAGONISTS; CENTRAL NERVOUS SYSTEM DISORDERS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-03-30 US disclosed